Avidity Biosciences 

Yahoo Finance • 30 days ago

Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating

We recently published 10 Stocks with Surprising Gains. Avidity Biosciences Inc. (NASDAQ:RNA) is one of the best performers on Friday. Avidity snapped a four-day losing streak on Friday, adding 9.02 percent to close at $44.74 apiece as inv... Full story

Yahoo Finance • last month

Avidity Biosciences prices $600M stock offering

* Avidity Biosciences (NASDAQ:RNA [https://seekingalpha.com/symbol/RNA]) has priced an upsized offering of 15M shares at $40 each to raise gross proceeds of $600M. * In addition, the biopharmaceutical company has granted the underwrite... Full story

Yahoo Finance • last month

Avidity Biosciences reports data from DMD treatment trials

[Muscular Dystrophy Handwritten With Blue Marker] IvelinRadkov/iStock via Getty Images Avidity Biosciences (NASDAQ:RNA [https://seekingalpha.com/symbol/RNA]) has announced new data from its clinical trials evaluating the experimental trea... Full story

Yahoo Finance • last month

Thursday's session: gap up and gap down stocks

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • last month

Stocks Climb as US Labor Market Weakness Bolsters Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • last month

Discover the top movers in Thursday's pre-market session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT YYGH [https://www.chartmill... Full story

Yahoo Finance • last month

Wednesday's after hours session: top gainers and losers

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE CO... Full story

Yahoo Finance • last month

Avidity Biosciences (NASDAQ:RNA) Exhibits High-Quality Technical Breakout Setup

Biotechnology firm AVIDITY BIOSCIENCES INC (NASDAQ:RNA [https://www.chartmill.com/stock/quote/RNA]) is currently presenting a notable technical profile, aligning with criteria often sought by momentum and breakout-focused investors. The st... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market

Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company focused on developing treatments for rare muscle diseases, has been making significant strides in its clinical programs and attracting attention from investors and analysts al... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences GAAP EPS of -$1.21 misses by $0.23, revenue of $3.8M beats by $2.19M

* Avidity Biosciences press release [https://seekingalpha.com/pr/20194023-avidity-biosciences-reports-second-quarter-2025-financial-results-and-recent-highlights] (NASDAQ:RNA [https://seekingalpha.com/symbol/RNA]): Q2 GAAP EPS of -$1.21... Full story

Yahoo Finance • 2 months ago

Avidity (RNA) Gets 26% Jump on Potential Takeover

We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences stock soars on Novartis takeover approach report

Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical giant Novartis (NYSE:NVS) has approached the rare disease-focused biotech company about a potential t... Full story

Yahoo Finance • 2 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

(Corrects typo in paragraph 1) (Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter (Reporting by Padmana... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences jumps on report of Novartis takeover approach

[Novartis CO building in Egypt, Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland] Tamer Soliman Avidity Bioscienes (NASDAQ:RNA [https://seekingalpha.com/symbol/RNA]) quickly soared 20% after a re... Full story

Yahoo Finance • 3 months ago

Avidity completes enrollment for phase 3 trial of DM1 treatment

SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), which has seen its stock surge over 24% year-to-date and maintains a market capitalization of $4.37 billion, announced Monday it has completed enrollment in its global Phase 3 HARBOR clin... Full story

Yahoo Finance • 3 months ago

Avidity Biosciences On Track To Seek Approval For Del-zota In DMD By Year-End

(RTTNews) - Avidity Biosciences Inc.'s (RNA) investigational ribonucleic acid therapy Del-zota has received Breakthrough Therapy designation from the FDA for the treatment of Duchenne muscular dystrophy in people living with mutations amen... Full story

Yahoo Finance • 4 months ago

Wolfe Research initiates Avidity Biosciences stock with outperform rating

Wolfe Research initiated coverage on Avidity Biosciences (NASDAQ:RNA) with an outperform rating and a price target of $55.00 on Tuesday. Currently trading at $29.80, the stock sits well below analyst targets, which range from $54 to $96. A... Full story

Yahoo Finance • 4 months ago

Avidity Biosciences' SWOT analysis: innovative RNA tech targets rare disease stock potential

Avidity Biosciences, Inc. (NASDAQ:RNA) is a biotechnology company focused on developing innovative treatments for rare muscular diseases. The company’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform technology aims to delive... Full story

Yahoo Finance • 4 months ago

Avidity Biosciences price target raised to $75 from $65 at Chardan

Chardan analyst Keay Nakae raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $65 and keeps a Buy rating on the shares after the company announced topline results from the dose escalation portion of the FORTITUDE trial... Full story